Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 7/20 | 0.40 |
| ▸ | MAPKAPK5 | Q8IW41 | 10/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | MAST3 | O60307 | 1/20 | 0.35 |
| ▸ | CD63 | P08962 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25823409 | 0.87 | MAPKAPK5 (0.43) | MAPK8MAPKAPK5SYKCD63 | |
| SCHEMBL26184439 | 0.86 | MAPK8 (0.38) | MAPK8MAPKAPK5SYKMAST3CD63 | |
| SCHEMBL25822750 | 0.82 | SYK (0.42) | MAPKAPK5SYKCD63 | |
| SCHEMBL25824383 | 0.79 | MAPK8 (0.43) | MAPK8MAPKAPK5SYKMAST3 | |
| SCHEMBL25822692 | 0.77 | MAPKAPK5 (0.51) | MAPKAPK5SYKCD63 | |
| SCHEMBL25823831 | 0.75 | SYK (0.49) | SYKCD63 | |
| SCHEMBL21949405 | 0.74 | PYGM (0.44) | — | |
| SCHEMBL21949415 | 0.72 | PYGM (0.43) | — | |
| SCHEMBL21949135 | 0.71 | PYGM (0.41) | SYK | |
| SCHEMBL25822754 | 0.71 | MAPKAPK5 (0.40) | MAPK8MAPKAPK5SYKTNKSCD63 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | SYK, KDR, FLT1 | MAPK8 637/4885MAPKAPK5 216/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.